Optimizing outcomes in advanced endometrial carcinoma: Guidelines, immunotherapy & irAE management

🧬 Three cases. Three key decision points. One evolving treatment landscape in advanced endometrial carcinoma. How do molecular features, staging and emerging evidence shape real-world treatment choices? Join Prof. Nicoletta Colombo and Dr Ilaria Colombo in this expert-led, case-based CME activity as they translate the latest guidelines into clinical decision-making. 👩‍⚕️ Across three patient cases, they explore: 🔬 How molecular classification is reshaping risk stratification and treatment selection 💊 First-line and second-line strategies in both dMMR and pMMR disease ⚠️ Best practices for recognising and managing immune-related adverse events 💬 “Molecular classification has completely changed the paradigm of treatment for these patients…” — Prof. Nicoletta Colombo 💬 “Patients with mismatch repair deficient tumours must receive an immune checkpoint inhibitor…” — Dr Ilaria Colombo 📈 From evidence to application—see how guideline updates influence real clinical choices. 🎓 Watch now to sharpen your decision-making and earn CME points: https://touchoncologyime.org/optimizi... This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. #EndometrialCancer #Oncology #GynaecologicOncology #Immunotherapy #CancerCare #MedicalEducation #CME #HCP #ClinicalDecisionMaking